Graduate Institute of Clinical Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan.
Division of Gastroenterology, Department of Internal Medicine, Yuan's General Hospital, Kaohsiung, Taiwan.
Expert Rev Anti Infect Ther. 2021 Sep;19(9):1071-1081. doi: 10.1080/14787210.2021.1874351. Epub 2021 Jan 17.
: Hepatitis C is one of the leading causes of chronic liver disease. The direct-acting-antivirals has revolutionized the chronic hepatitis C treatment. DAAs can achieve a sustained virological response rate >95% in different populations.: This review summarizes the pharmacokinetics, pharmacodynamics, efficacy, and safety of Elbasvir/Grazoprevir (EBR/GZR).: EBR/GZR is a combination of NS5A and NS3/4A inhibitors. The performance in the EBR/GZR combination's safety and tolerability is appreciated in clinical treatment. EBR/GZR also has a higher barrier to resistance-associated substitutions. Based on clinical trials and real-world experience, elbasvir/grazoprevir is effective in the HCV GT1, 4 infections.
丙型肝炎是慢性肝病的主要原因之一。直接作用抗病毒药物改变了慢性丙型肝炎的治疗方法。不同人群的直接作用抗病毒药物的持续病毒学应答率>95%。本综述总结了 Elbasvir/Grazoprevir（EBR/GZR）的药代动力学、药效学、疗效和安全性。EBR/GZR 是 NS5A 和 NS3/4A 抑制剂的组合。EBR/GZR 组合在临床治疗中的安全性和耐受性表现出色。EBR/GZR 对耐药相关替代物的抵抗力也更高。基于临床试验和真实世界的经验，Elbasvir/Grazoprevir 对 HCV GT1、4 感染有效。
